Eve Fertility has successfully completed the second milestone of the HKSTP Ideation Phase programme. The achievement triggered the release of the second grant tranche, supporting continued development and pre-deployment readiness for EVEA™ across Asia-Pacific. The HKSTP Ideation Phase programme provides early-stage funding and validation for deep-tech startups emerging from Hong Kong innovation labs.
Eve Fertility's patent application for the EVEA™ platform has been granted by the Hong Kong Intellectual Property Department (HKIPD). The granted patent provides intellectual-property protection for the core innovation underlying EVEA™ — the engineered intravaginal culture platform — in Hong Kong and the broader Asia-Pacific region where Eve is focused on deployment and partnership.
A granted patent represents formal recognition of novelty and inventive step, strengthening Eve's IP position and providing commercial protection for the EVEA™ technology platform.
Eve Fertility was selected as one of ten finalists in the EQT Impact Challenge global competition, competing alongside innovative startups across healthcare, climate, and social impact. The challenge evaluated Eve Fertility's model for expanding reproductive-technology access and the economic impact of decentralized embryo culture in underserved Asian markets.
Eve Fertility's patent application for the EVEA™ platform has passed its independent substantive search. The China National Intellectual Property Administration (CNIPA) assessed the application's claims against the global body of published prior art — including patents, scientific literature and technical disclosures relating to intravaginal culture devices.
The resulting search report concluded that the core claims are novel and inventive over the cited prior art. A favourable substantive search report is a meaningful independent indicator that the technology is differentiated from existing solutions, and a significant step in building Eve's intellectual-property position — particularly in China, one of the most significant jurisdictions for fertility innovation.
A substantive search report reflects the examiner's assessment of novelty and inventive step over the cited prior art; it is a step in the examination process and does not itself constitute a granted patent.
Eve Fertility has advanced to the next stage of the MedTech Innovator Asia Pacific 2026 Accelerator Program — one of the world's largest MedTech accelerators — and was invited to pitch in person at the MedTech Innovator Pitch Event in Singapore on 14–15 April 2026, presenting our vision for expanding fertility-treatment capacity across APAC to investors, industry leaders and strategic partners.
More details are on the MedTech Innovator website.
Eve Fertility was selected as one of the Top 10 finalists for the Alpha Startups™ INNO4HER 2026 FemTech Accelerator, organised by 1337 Ventures. Selected from a competitive global pool, the cohort represents startups from Malaysia, Singapore, Hong Kong, the Philippines and Poland, with a focus on innovations that improve women's health through clinical depth and structural impact.
The accelerator provided mentorship from industry experts, culminating in a Demo Day on 31 March 2026 at Microsoft Malaysia. Read the full announcement on Disruptr.
Eve Fertility has signed a Letter of Intent (LOI) with Vietnam Belgium Andrology and Fertility Hospital (VBH), one of Vietnam's leading fertility centres, marking a formal step toward exploring how EVEA™ intravaginal culture could support VBH's clinical team in offering more affordable treatment options for Vietnamese patients.
The Letter of Intent sets out a shared intent to evaluate a defined pilot of IVC-based fertility care, drawing on VBH's established clinical infrastructure and patient base to assess clinical suitability for patients currently underserved by cost or access barriers.
The Letter of Intent is non-binding and reflects a shared intent to explore collaboration; any pilot is subject to applicable regulatory approvals and definitive agreements.
Eve Fertility and the intravaginal-culture space have attracted attention from regional business and health-tech media. Details of active media partnerships and press coverage are shared under confidentiality with partners.
For press inquiries, interviews, or coverage discussion: Reach out via contact form (select "Media & Press" category)
Updates on EVEA™ deployment, partnerships, and regional expansion across Asia-Pacific.
Follow on LinkedIn → Contact us